Interactive homeostatic mechanisms exist between cells from the time of blastula formation. These regulatory processes are usually able to maintain tissue integrity through all phases of life and can be regarded as mechanisms of """"""""non-immune surveillance"""""""" against neoplasia. Immune mechanisms for surveillance also exist, but little is known of how non-immune and immune surveillance might interface to control the emergence of malignant growths. Normal mammary gland tissue interactions occur in the embryo and continue through puberty, child bearing, and menopause. A progression of tissue interactions occurs from the 11 day (in utero) fetal mammary bud to the aberrant tissues of malignant tumors. I have demonstrated that mammary tumor growth is augmented by normal mammary gland tissues in the mouse and that the mechanism of that site preference is probably not due to the immunologically privileged nature of the fatpad. I have also shown that, despite the preference of the tumor cells for the mammary site, metastatic tumor cells metastasize more readily from the fatpad than the subcutis. I wish to continue my investigations of mammary tumors growing in their natural anatomic site to determine both the mechanism of the site preference and its consequences. The study of the mechanism will continue to focus on cellular interactions within the mammary gland fatpad. Interactions between tumor cells and non-lymphoid cells (normal glandular tissue, preneoplastic lesions, and other tumors), between tumor and lymphoid cells, and between lymphoid and non-lymphoid cells of the mammary gland will be investigated both in vitro and in vivo. The studies of the consequences will focus on the affect of mammary gland tissue interactions on progression. Eventually, manipulation of tissue interactions could lead to new therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA028366-06
Application #
3168098
Study Section
Pathology B Study Section (PTHB)
Project Start
1980-06-01
Project End
1986-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
6
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Barbara Ann Karmanos Cancer Institute
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48201
Santner, S J; Dawson, P J; Tait, L et al. (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65:101-10
Miller, F R (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:379-91
Strickland, L B; Dawson, P J; Santner, S J et al. (2000) Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 64:235-40
Wang, B; Miller, F R (2000) Tyrosine phosphorylation of an erbB-2 related p90 protein induced by estrogen in human breast epithelial cells. Int J Oncol 16:1035-42
Miller, F R; Barnbabas, N; Liu, X et al. (1999) Differential display, subtractive hybridization, and application of methodology to search for point mutations to identify genetic defects responsible for progression in MCF10AT model of human breast disease. Electrophoresis 20:256-60
Iravani, S; Mora, L; Miller, F R et al. (1998) Altered expression of c-erbB-2, DF3, b72.3, p53 and Ki-67 with progression and differentiation to two distinct histologic types of invasive carcinoma in the MCF10AT human xenograft model of proliferative breast disease. Int J Oncol 12:369-75
Wang, B; Soule, H D; Miller, F R (1997) Transforming and oncogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines. Anticancer Res 17:4387-94
Wolman, S R; Heppner, G H; Wolman, E (1997) New directions in breast cancer research. FASEB J 11:535-43
Miller, F R (1996) Models of progression spanning preneoplasia and metastasis: the human MCF10AneoT.TGn series and a panel of mouse mammary tumor subpopulations. Cancer Treat Res 83:243-63
Miller, F R; Pauley, R J; Wang, B (1996) Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. Anticancer Res 16:1765-9

Showing the most recent 10 out of 43 publications